-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted...
IN THE SPOTLIGHT
-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Lung cancer remains the leading cause of cancer death worldwide. Over the past two decades, the development of targeted therapies, particularly tyrosine kinase inhibitors (TKIs)... -
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community.
SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma
SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma
Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement
Identification of a personalized eGFR threshold improves the prediction of kidney failure risk after transplantation
Identification of a personalized eGFR threshold improves the prediction of kidney failure risk after transplantation
[177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study
[177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study
Discovery of novel 1,2,3-Triazole hybrids containing quinoline-imidazole moieties as EGFR/HER2 dual inhibitors
Discovery of novel 1,2,3-Triazole hybrids containing quinoline-imidazole moieties as EGFR/HER2 dual inhibitors
Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients
Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients
Osimertinib Combo Boosts PFS in EGFR/TP53+ NSCLC Trial
2026 ELCC｜PALOMA-2 研究队列 1 数据更新：埃万妥单抗皮下剂型联合兰泽替尼用于 EGFR 经典突变 NSCLC 一线治疗证据进一步成熟_腾讯新闻
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models